Compare Box Inc (BOX) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs Nuvalent Inc — how do they compare? Box Inc trades at $30.14 (market cap $4.16B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 2.4× Box Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, Box Inc nearer its low. Which is the better fit depends on your goals.
| BOX | NUVL | |
|---|---|---|
Market Cap | $4.16B | $9.81B |
Sector | Technology | Technology |
52-Week High | $33.55 | $123.96 |
52-Week Low | $21.37 | $72.16 |
Enterprise Value | $4.71B | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX trades at $29.41, up 2.69% today, near its consensus price target low of $29.00. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.09B in 2025 with net income surging to $244.62M, reflecting a robust profit margin expansion. Recent earnings beats in Q4 2025 and Q1 2026 support positive sentiment, while the company expanded Box Zones globally to enhance data governance (Business Wire, 2026-06-30).
The outlook remains favorable with a $37.00 analyst price target implying 26% upside, backed by 60.7% buy ratings. Key risks include high P/E of 45.95 suggesting premium valuation, competitive pressures in content management, and debt levels requiring monitoring. Positive cash flow trends and strategic expansions provide growth catalysts, but investors should weigh valuation concerns against earnings momentum.
Nuvalent (NUVL) trades at $123.94, showing minimal daily movement with a 0.03% gain. The stock is in focus following GSK's proposed acquisition at $124 per share, announced June 2026. Technically, the price is at the acquisition offer level with a bullish moving average signal but overbought RSI readings. Fundamentally, the company reports significant losses with negative ROE and ROA, while cash flow remains supported by financing activities.
The investment outlook is dominated by the pending acquisition, limiting upside beyond the offer price. Key risks include deal completion uncertainty and ongoing operational losses. Analyst sentiment is mixed with a slight hold bias, reflecting caution until transaction closure. Shareholder value hinges on successful deal execution amid financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
